Legal notice: Anabolic-androgenic steroids (AAS) are Class C controlled substances under the Misuse of Drugs Act 1971 in the UK. Possession is not illegal, but supply without a licence is a criminal offence. All AAS require a prescription to be dispensed legally. This guide is educational only. It does not constitute medical advice or a recommendation to use any compound.
A direct message before you read further: If you are under 25, this guide is not a protocol. It is a warning. The physiological consequences of AAS use during development are irreversible in some cases. Please read the section on age-related risks before anything else. There is no compound in this guide worth the cost of a permanently disrupted endocrine system during the years when your testosterone axis is still completing its development.
Why This Guide Exists
There is a problem with how AAS information is distributed online. The two dominant sources are:
-
Underground forums and social media — where use is glamorised, side effects are minimised, and young men are the primary audience. The cultural message is that AAS are a shortcut to the physique you want, not a serious medical intervention with lasting consequences.
-
Medical literature — accurate but inaccessible to most people. Clinical language, paywalled journals, and no practical framing for someone trying to understand what these compounds actually do to the human body.
The gap between these two extremes is where most young men make uninformed decisions. This guide attempts to fill it: clinical accuracy, honest risk assessment, and a consistent safety message.
These compounds are used in legitimate medical contexts — hypogonadism, HIV wasting, anaemia, delayed puberty, gender-affirming care, and others. This guide covers their pharmacology, risks, and the medical evidence base. It does not provide sourcing information and does not frame non-prescribed use as a reasonable lifestyle choice.
The Biology You Need to Understand First
The Hypothalamic-Pituitary-Gonadal (HPG) Axis
Testosterone is not produced in isolation. It is produced through a chain of hormonal signals:
- The hypothalamus releases GnRH (gonadotropin-releasing hormone) in pulses
- GnRH signals the pituitary to release LH (luteinising hormone) and FSH
- LH signals the Leydig cells in the testes to produce testosterone
- FSH signals Sertoli cells to support sperm production
This is called the HPG axis. It is a feedback loop — when testosterone levels rise, the hypothalamus and pituitary detect this and reduce GnRH/LH/FSH. When testosterone falls, they increase production to compensate. The body has finely tuned this system over millions of years of evolution.
What exogenous AAS do to this system:
When you introduce synthetic androgens from outside the body, the hypothalamus and pituitary detect elevated androgens and shut down GnRH, LH, and FSH production. The testes stop receiving the signal to produce testosterone. They shrink (testicular atrophy) and cease both testosterone and sperm production.
This suppression begins within days of starting any exogenous androgen. The degree of suppression is dose and compound-dependent but is essentially complete on any meaningful AAS cycle.
Recovery of the HPG axis after stopping AAS:
In adults with a fully developed HPG axis, recovery typically occurs over 3–6 months post-cycle, assuming no permanent damage. In some men, particularly those who use AAS at high doses or for extended periods, the axis does not fully recover. Hypogonadism — a clinical testosterone deficiency requiring lifetime treatment — can result.
In men under 25, the risk is categorically higher. The HPG axis is still completing its functional development through the early-to-mid twenties. Suppressing it during this window carries a higher risk of permanent disruption than suppressing an already-mature system.
The Age Question: Why Under 25 Is a Categorically Different Risk Profile
This section is written specifically for younger readers considering AAS, and it contains information that the majority of online sources will not give you.
1. The HPG Axis Is Still Developing
Testosterone axis maturation continues into the early-to-mid twenties in many men. Introducing exogenous androgens during this period risks permanently disrupting this developmental process. The clinical literature on post-cycle hypogonadism shows disproportionate rates of non-recovery in men who began AAS use before age 25. [Source: Rahnema et al., 2014 — Anabolic steroid-induced hypogonadism: diagnosis and treatment — Fertility and Sterility]
2. You Are Already at Your Testosterone Peak
Male testosterone production peaks in the late teens to early-to-mid twenties. The natural anabolic environment at this age — combined with progressive overload training and adequate nutrition — produces the fastest natural muscle gains you will ever experience. AAS use during this window provides the smallest relative benefit and the largest relative risk of any point in a man's life.
3. Epiphyseal Plate Closure
In men whose bone growth plates (epiphyseal plates) have not fully closed — typically by age 18–21 but variable — high-dose androgen exposure can cause premature closure. This means your long bones stop growing. You may permanently end up shorter than your genetic potential. This is well-documented in the clinical literature on androgen use in adolescents. [Source: Rogol et al. — endocrine effects of supraphysiological androgen exposure in adolescence]
4. You Cannot Know Your Genetic Susceptibility
Some men have a genetic predisposition to:
- Permanent HPG axis suppression
- Severe androgenic side effects (hair loss acceleration, acne, sebaceous gland hypertrophy)
- Elevated haematocrit risk
- Gynecomastia that requires surgical correction
You will not know your profile until you have already taken the first dose. There is no test that predicts this in advance.
5. The Mental Health Data
Multiple studies have documented elevated rates of depression, hypomania, aggression dysregulation, and dependent use patterns in AAS users. [Source: Mullen et al., 2020 — The adverse effects of anabolic steroids on the heart — Heart; Pope et al. — multiple papers on AAS and psychological effects] A developing brain and endocrine system is more vulnerable to these effects than an adult one.
The honest summary: If you are under 25, you are at the peak of your natural anabolic potential. You have more to gain from training, eating, and sleeping well than from any compound in this guide — and the risks are asymmetric: the downside is permanent endocrine damage during development; the upside is accelerating a process that is already happening naturally.
Compound Profiles
Nandrolone Decanoate (Deca-Durabolin) and Nandrolone Phenylpropionate (NPP)
Class: 19-nortestosterone (nandrolone) derivative
Anabolic:Androgenic ratio: 125:37 (compared to testosterone's 100:100)
Aromatisation: Low (converts to oestradiol at approximately 20% the rate of testosterone)
Progestogenic activity: Significant — nandrolone has strong progesterone receptor affinity
Two Esters, Two Half-Lives
Nandrolone Decanoate (Deca): The long ester. Half-life approximately 6–12 days. Weekly or twice-weekly injection. The classic form. Takes several weeks to reach steady state and several weeks to clear post-cycle. This creates a long suppression tail — HPG axis suppression continues for weeks after the last injection.
Nandrolone Phenylpropionate (NPP): The short ester. Half-life approximately 2–4 days. Injected every other day or 3× weekly for stable levels. Reaches steady state faster. Clears faster. Preferred when shorter cycle duration or more control is wanted.
Mechanism
Nandrolone binds the androgen receptor with slightly lower affinity than testosterone but is 5-alpha reduced to a weaker androgen (dihydronandrolone) by 5-alpha reductase — the opposite of testosterone, which is 5-alpha reduced to the potent DHT. This is why nandrolone has a lower androgenic side effect profile at the tissue level in skin, scalp, and prostate, relative to its anabolic effect.
Clinical Applications
Nandrolone decanoate is or has been licensed for:
- Osteoporosis treatment (UK licence — used for post-menopausal bone loss)
- Anaemia associated with renal insufficiency
- Wasting conditions (cachexia, HIV-related muscle wasting)
- Aplastic anaemia
There is a meaningful clinical evidence base from these applications. Studies show nandrolone increases lean mass, improves nitrogen balance, and increases bone mineral density. [Source: Johansen et al. — nandrolone in dialysis patients; Evans, 2004 — Current concepts in anabolic-androgenic steroids]
Known Risks — Nandrolone Specific
Progesterone receptor activity. Nandrolone's progestogenic action is the most clinically significant nandrolone-specific risk. Progesterone receptor activation:
- Amplifies the gynecomastia risk, particularly in combination with any oestrogen from other compounds. Men prone to gynecomastia have higher risk on nandrolone than on compounds with equivalent oestrogen conversion.
- Can cause or exacerbate sexual dysfunction through a different mechanism than oestrogen imbalance — the so-called "deca dick" phenomenon. This is progesterone-mediated libido suppression and erectile dysfunction. It is dose-dependent and resolves with cessation in most cases, but not all.
Cardiovascular: All AAS negatively impact cardiovascular markers. Nandrolone causes LDL cholesterol elevation, HDL suppression, and left ventricular hypertrophy with extended use. [Source: Hartgens & Kuipers, 2004 — Effects of androgenic-anabolic steroids in athletes — Sports Medicine]
HPG axis suppression: As with all AAS, complete suppression. The long half-life of deca means suppression persists significantly after the last injection. Post-cycle recovery is typically slower after nandrolone than after shorter-acting compounds.
Psychiatric: All androgens used supratherapeutically are associated with mood disruption, irritability, and in susceptible individuals, hypomanic or aggressive episodes. [Source: Pope HG et al. — multiple papers on AAS psychiatric effects]
Clinical Context
In supervised TRT settings, low-dose nandrolone (50–100mg/week) is sometimes added to testosterone protocols to support joint health and connective tissue — there is preclinical and anecdotal clinical evidence for this benefit, and it is the one application where a case exists for monitored adult use. This is a very different context from the 300–600mg/week doses used in non-medical settings.
Oxandrolone (Anavar)
Class: 17-alpha alkylated dihydrotestosterone derivative
Anabolic:Androgenic ratio: 322–633:24 (extremely high anabolic, very low androgenic)
Aromatisation: None — oxandrolone does not convert to oestrogen
Hepatotoxicity: Yes — oral 17-alpha alkylated compound
Background
Oxandrolone was synthesised in 1962 by Searle Laboratories specifically to have a high anabolic-to-androgenic ratio. It is still manufactured under various brand names (Anavar being the original trade name) and has more active medical approvals than most AAS compounds:
- Paediatric growth failure: FDA-approved for constitutional growth delay in boys
- HIV wasting: Evidence-based use in adult men and women
- Severe burns: Oxandrolone significantly improves lean mass recovery and wound healing in burn victims — this is among the most robust AAS clinical evidence bases [Source: Jeschke et al. — oxandrolone in burn care; Hart et al., 2001 — NEJM — paediatric burns]
- Catabolic disease states: Including post-surgical recovery
- Osteoporosis in women: Approved in some countries
Why It Has a Reputation for Being "Mild"
Oxandrolone's low androgenicity means the androgenic side effects (acne, hair loss acceleration, prostatic effects) are genuinely lower than testosterone or nandrolone. Its inability to aromatise means no oestrogen-related side effects. Its low virilising effect is why it was, historically, more commonly prescribed to women and children.
However "mild androgenic side effects" does not mean safe. The hepatotoxicity is real. The HPG axis suppression is real. The cardiovascular impact is real.
Known Risks — Oxandrolone Specific
Hepatotoxicity. Oxandrolone, like all oral 17-alpha alkylated compounds, is structurally modified to survive first-pass liver metabolism. This modification causes direct liver stress:
- Elevated liver enzymes (ALT, AST) are universal with oral AAS use
- With extended use or higher doses, progression to cholestatic hepatitis, peliosis hepatis (blood-filled cysts in the liver), and liver adenoma is possible
- These conditions are potentially fatal
- TUDCA and UDCA supplementation reduces but does not eliminate hepatotoxicity
- Blood monitoring of liver function is non-negotiable during any oral AAS use
[Source: Maravelias et al., 2005 — Adverse effects of anabolic steroids in athletes — Toxicology Letters; multiple case reports in clinical literature]
Lipid profile: Despite low androgenicity, oxandrolone has a severe negative impact on cholesterol — particularly HDL suppression, which is disproportionately bad relative to other AAS at equivalent anabolic effect. Studies in burn patients show HDL reductions of 40–50% during oxandrolone treatment. Cardiovascular risk accumulates with lipid disruption duration.
HPG suppression: Lower dose-for-dose than testosterone, but suppression occurs. In men, oxandrolone at therapeutic doses still suppresses gonadotropins measurably. At non-medical doses, suppression is more complete.
The "mild" myth for younger users: Oxandrolone is frequently presented in online communities as the appropriate "first AAS" for young men due to its low androgenicity. This is misleading. Hepatotoxicity from oral 17-aa compounds is cumulative and dose-duration dependent. The HPG axis suppression is real. A 19-year-old causing liver damage and disrupting his still-developing HPG axis is not taking something "mild" — he is trading long-term health for accelerated aesthetics.
Stanozolol (Winstrol)
Class: 17-alpha alkylated dihydrotestosterone derivative
Anabolic:Androgenic ratio: 320:30
Aromatisation: None
Available forms: Oral (17-aa) and injectable (aqueous suspension)
Hepatotoxicity: Yes (oral form; injectable form also hepatotoxic, though less so)
Background
Stanozolol is most widely known culturally for its association with Ben Johnson's 1988 Olympic doping disqualification. It is approved in the US for hereditary angioedema and has historical use in aplastic anaemia and some wasting conditions.
It is notably used in veterinary medicine for horses — a detail worth holding in mind when assessing the "research" base that often circulates in online communities.
Mechanism
DHT derivative with the same structural modification as oxandrolone (17-alpha alkylation) plus an additional pyrazole group fused to the A-ring. This structure prevents aromatisation (no oestrogen) and reduces binding to SHBG, meaning a higher proportion of the compound is free and active.
The SHBG-binding interference means stanozolol can increase free testosterone when used alongside other compounds — this is the basis of "stacking" rationales.
Known Risks — Stanozolol Specific
Joint pain. Stanozolol is associated with significant connective tissue and joint side effects that are unusual among AAS. The mechanism is not fully established but likely relates to collagen synthesis disruption and the reduction in oestrogen (which has joint-protective effects). Men commonly report joint pain, tendon issues, and reduced range of motion during stanozolol use. In athletes who need joint integrity for performance, this is a significant limiting factor.
Cardiovascular — lipid profile. Stanozolol has one of the most negative lipid profiles of any AAS in the clinical literature. HDL reduction is severe — studies in athletes show reductions of 50%+ from baseline [Source: Hartgens & Kuipers, 2004]. This is not a theoretical risk; it is a documented, consistent finding. Sustained HDL suppression at this magnitude substantially elevates atherosclerosis risk.
Hepatotoxicity: Both oral and injectable forms cause liver stress, though the injectable aqueous form is less hepatotoxic than the oral 17-aa form. The same caution applies — liver monitoring is mandatory.
Androgenic side effects: DHT-derived compound with strong binding at androgen receptors in skin and scalp. Men with genetic predisposition to male pattern hair loss will experience accelerated loss. Acne can be severe.
HPG suppression: As with all AAS.
Clinical Context
The angioedema indication is legitimate and stanozolol has evidence in that specific context. Outside of clinical use, the joint-pain and lipid-profile side effects make it among the less appealing compounds on a risk:benefit analysis compared to alternatives.
Boldenone Undecylenate (Equipoise / EQ)
Class: Modified testosterone with double bond between carbon 1 and 2
Anabolic:Androgenic ratio: 100:50 (anabolic similar to testosterone, half the androgenicity)
Aromatisation: Approximately 50% the rate of testosterone
Half-life: 14 days (very long ester — undecylenate)
Origin: Veterinary compound (horses, cattle)
Background
Boldenone was synthesised as a potential long-acting injectable testosterone analogue. It was never approved for human use in most countries — its clinical use has primarily been veterinary. This is a significant point that online communities consistently understate.
The fact that a compound has been used in horses does not mean it has equivalent safety characterisation in humans as compounds that have completed human clinical trials. The clinical literature on boldenone in humans is limited compared to nandrolone or oxandrolone.
Mechanism
The 1,2-double bond in boldenone's structure reduces aromatisation relative to testosterone and reduces androgenic side effects by altering the compound's 5-alpha reduction profile. Boldenone does not 5-alpha reduce to a potent androgen. Its aromatisation to a unique oestrogen metabolite (boldenone oestrogen) has different properties than oestradiol.
Unique Haematological Effect
Boldenone substantially increases erythropoietin (EPO) production — more so than most other AAS. This drives significant haematocrit and haemoglobin elevation, increasing red blood cell mass. This is part of its historical athletic use for endurance sports.
The cardiovascular implication: elevated haematocrit increases blood viscosity and thrombosis risk. At high haematocrit levels (above 52–54%), the risk of stroke, DVT, and pulmonary embolism rises substantially. This is the same risk as TRT-induced erythrocytosis, but typically more pronounced with boldenone.
Known Risks — Boldenone Specific
Haematocrit elevation: The most clinically significant boldenone-specific risk. Regular haematocrit monitoring is essential. Blood donation can manage mild elevation; significant elevation may require cessation.
Anxiety and anxiety-like states: Boldenone is associated with a higher rate of anxiety and paranoia-like states than most other AAS in user reports and in the limited clinical literature available. The mechanism is not well-characterised but may relate to its unique oestrogen metabolite and central nervous system androgenic activity.
Very long half-life: The undecylenate ester produces a half-life of approximately 14 days. This means the compound takes 8–12 weeks to fully clear the system after the last injection. HPG axis suppression persists for this entire period. Recovery is slow after boldenone use.
Limited human clinical data: The relative lack of human clinical trials (versus nandrolone or oxandrolone, which have legitimate medical use histories) means the full risk profile in humans is less well characterised.
Drostanolone (Masteron) — Propionate and Enanthate
Class: 2-alpha methyl-dihydrotestosterone derivative
Anabolic:Androgenic ratio: 62–130:25–40
Aromatisation: None (DHT derivative — cannot aromatise)
Forms: Drostanolone Propionate (half-life 2–3 days) and Drostanolone Enanthate (half-life 7–10 days)
Background
Drostanolone was developed in the 1950s and approved for treatment of inoperable breast cancer in women — its anti-oestrogenic properties (via aromatase inhibition and competitive oestrogen receptor binding) were the clinical rationale. It has been largely superseded by SERMs and aromatase inhibitors in oncology but was in legitimate clinical use for decades.
Mechanism
As a DHT derivative, drostanolone cannot aromatise to oestrogen. Beyond this, it has mild aromatase-inhibiting properties — it competes for the aromatase enzyme, reducing the conversion of other androgens to oestrogen. This is why it is used in combination protocols to manage oestradiol without pharmaceutical aromatase inhibitors.
The 2-methyl group modification increases anabolic activity relative to DHT while retaining the non-aromatising property.
Known Risks — Drostanolone Specific
Strong androgenic side effects: Despite moderate anabolic rating, drostanolone is a potent androgen in DHT-sensitive tissues. Accelerated male pattern hair loss in genetically predisposed men is significant and often severe. If you have any family history of male pattern baldness and have not yet begun losing hair, drostanolone is likely to accelerate this substantially and potentially irreversibly.
Cardiovascular — lipid impact: Like all DHT derivatives, drostanolone causes HDL suppression and LDL elevation. The combination with no oestrogenic activity (oestrogen has cardioprotective effects) means the net cardiovascular risk profile is meaningful.
HPG suppression: As with all AAS.
The "anti-oestrogen" misunderstanding: Drostanolone's anti-oestrogenic properties are relative and dose-dependent. It is not an aromatase inhibitor in the pharmaceutical sense. Using it as a substitute for proper oestrogen management is clinically unsound.
Side Effects Common to All AAS
Cardiovascular Risk
This is the most clinically significant risk across all AAS compounds and deserves emphasis beyond what most online sources provide.
Left ventricular hypertrophy (LVH): AAS cause pathological hypertrophy of the left ventricle — the heart's main pumping chamber. This is different from exercise-induced cardiac adaptation (which is generally beneficial). AAS-induced LVH is associated with reduced diastolic function, increased arrhythmia risk, and in severe cases, sudden cardiac death. Multiple studies document LVH in AAS users. [Source: Achar et al., 2010 — Cardiac and metabolic effects of anabolic-androgenic steroid abuse on lipids, blood pressure, left ventricular dimensions, and rhythm — American Journal of Cardiology]
The LVH appears to be at least partially reversible after cessation, but long-term users may have permanent structural changes.
Lipid profile: All AAS, to varying degrees, reduce HDL cholesterol (the protective "good" cholesterol) and elevate LDL. The magnitude varies by compound and oral vs. injectable route, but no AAS compound has a neutral or positive cardiovascular lipid profile. Sustained lipid disruption over years is a major driver of the elevated cardiovascular mortality seen in long-term AAS users. [Source: Baggish et al., 2017 — Cardiovascular toxicity of illicit anabolic-androgenic steroid use — Circulation]
Polycythaemia / erythrocytosis: Elevated red blood cell mass from AAS-induced EPO stimulation increases blood viscosity and thrombosis risk.
Atherosclerosis: Long-term AAS users show accelerated coronary artery atherosclerosis in imaging studies. The combination of LVH and coronary disease is a high-risk profile for cardiac events at relatively young ages. [Source: Baggish et al., 2017]
Hormonal and Reproductive
HPG axis suppression and post-cycle recovery failure: The risk of permanent hypogonadism is real. Men who require TRT in their 30s due to prior AAS use are well-documented in clinical practice.
Fertility: Sperm production is suppressed completely during AAS use. Recovery can take 6–24 months post-cycle. In some men, particularly those with extended use history, recovery is incomplete.
Gynaecomastia: Development of glandular breast tissue. In some cases this requires surgical correction (mastectomy). It is not simply water retention and does not always reverse with cessation — once the gland develops, surgery is the only effective treatment.
Psychological
Mood dysregulation: Irritability, aggression, and mood instability during use; depression, low energy, and anhedonia during post-cycle withdrawal are consistently documented. [Source: Pope et al. — multiple papers, AAS and the brain]
Dependency: AAS use carries a genuine risk of psychological and physiological dependency. The cycle of use → withdrawal → restart is well-documented, and the psychological aspect (body dysmorphia, fear of losing gains) is a recognised clinical pattern.
Hepatic (Oral 17-alpha alkylated compounds only)
- Elevated liver enzymes (universal, dose-dependent)
- Cholestatic hepatitis
- Peliosis hepatis
- Hepatocellular carcinoma (rare, but documented with long-term use)
Monitoring Markers: If You Are Going to Be Informed
This section is included because adults who use AAS do so with or without access to medical oversight. The responsible approach is to understand what needs to be monitored.
Before Starting
- Full hormone panel: testosterone, LH, FSH, oestradiol, prolactin, SHBG
- Lipid panel: total cholesterol, HDL, LDL, triglycerides
- Liver function tests (ALT, AST, GGT, ALP, bilirubin)
- Haematocrit and full blood count
- Blood pressure
- Cardiovascular baseline (ECG, ideally echocardiogram for LV function)
- PSA (men over 40)
During Use (Every 4–6 Weeks at Minimum)
- Liver function (oral compounds especially — urgent if ALT >3× upper limit of normal)
- Haematocrit (do not exceed 52–54%)
- Blood pressure
- Oestradiol management markers
Post-Cycle
- LH, FSH (HPG axis recovery markers — should begin recovering within 4–8 weeks of last injection)
- Total testosterone (confirms HPG axis recovery)
- Lipid panel (recovery of lipid profile)
- Liver function (should normalise within weeks of stopping oral compounds)
If LH and FSH do not recover within 3–4 months post-cycle, this warrants referral to an endocrinologist. Persistent post-cycle hypogonadism is a clinical condition requiring medical management, not a situation to manage alone.
Post-Cycle Therapy (PCT): The Evidence Base
PCT refers to the use of selective oestrogen receptor modulators (SERMs) — typically tamoxifen (Nolvadex) and/or clomiphene (Clomid) — after an AAS cycle to stimulate recovery of the HPG axis.
The rationale: SERMs block oestrogen receptors at the hypothalamus and pituitary, removing the negative feedback signal. The hypothalamus and pituitary respond by increasing GnRH, LH, and FSH, which signals the testes to restart testosterone production.
The evidence: Small clinical studies and substantial clinical experience support that SERM-based PCT reduces time to HPG axis recovery compared to no PCT, and reduces the risk of prolonged post-cycle hypogonadism.
Standard PCT protocol:
- Tamoxifen: 20mg/day for 6–8 weeks post-cycle (or 40mg for 2 weeks then 20mg for 4 weeks)
- With or without clomiphene (25–50mg/day) — combination has some evidence of enhanced recovery but also higher side effect burden
What PCT does not do:
- PCT does not guarantee HPG axis recovery — in men with significant prior use, recovery may be incomplete regardless
- PCT is not a safety net that removes the risks of AAS use
- PCT does not address cardiovascular, hepatic, or psychological side effects
The Legal Framework in the UK
| Compound | UK Legal Status | |----------|----------------| | Nandrolone (Deca, NPP) | Class C controlled substance. Possession legal; supply without licence is criminal | | Oxandrolone (Anavar) | Class C. Genuine pharmaceutical product exists (rare); vast majority of what's sold is unverified | | Stanozolol (Winstrol) | Class C. Original pharmaceutical manufacture largely discontinued; almost entirely grey-market | | Boldenone (Equipoise) | Class C. Never had human pharmaceutical approval; veterinary compound | | Drostanolone (Masteron) | Class C. Historical pharmaceutical use; now almost entirely grey-market |
The grey-market quality problem: With the exception of compounds manufactured by licensed pharmaceutical companies (which represent a tiny fraction of what circulates in the AAS market), the vast majority of what is sold is manufactured in unlicensed underground labs with no independent quality verification. Studies of seized AAS products routinely find:
- Mislabelled compounds (sold as one compound, actually another)
- Incorrect concentrations
- Bacterial contamination
- Particulates
- Heavy metal contamination
This is a direct health risk independent of the risks from the correctly-labelled compound itself.
If You Have Already Used AAS and Are Experiencing Issues
Signs Your HPG Axis Has Not Recovered
- Persistent low energy, low libido, depression, and brain fog beyond 3–4 months post-cycle
- Morning erections absent or markedly reduced
- Testicular atrophy not resolving
These symptoms warrant blood testing (LH, FSH, total testosterone). If testosterone is low and LH/FSH are also low, this indicates central hypogonadism — the pituitary is not signalling the testes. This may respond to SERM therapy under medical supervision, or may require TRT.
See a GP or a private endocrinologist. Persistent post-cycle hypogonadism is treatable but requires proper diagnosis. Do not self-manage this indefinitely.
UK Resources
- GP: First port of call. Request hormone panel if you describe symptoms. Many GPs are not AAS specialists but can order blood tests and refer.
- UKAT (UK Addiction Treatment): If dependency is a concern — ukat.co.uk
- Release (UK drug policy): Harm reduction and legal advice — release.org.uk
- Frank (UK drug information): frank.gov.uk/drug/anabolic-steroids — honest, non-judgemental information and support referrals
The Short Version
Anabolic-androgenic steroids are pharmacologically active compounds with legitimate medical applications and serious, documented health risks. The risks include permanent HPG axis disruption, cardiovascular structural damage (LVH, accelerated atherosclerosis), hepatotoxicity (oral compounds), permanent reproductive consequences, and psychological dependency. These risks are not theoretical — they are documented in peer-reviewed clinical literature and in clinical practice.
These are not lifestyle supplements. They are not shortcuts that come without cost. The cost is borne later, often during the years when health matters most.
If you are under 25: you are at your peak natural anabolic potential. There is nothing in this guide worth the risk of disrupting your HPG axis during development. The men who made that trade in their teens and early twenties are not posting the consequences on the same forums where the cycles are discussed.
If you are an adult considering any of these compounds: medical supervision is not optional. It is the only responsible framework.
This guide cites peer-reviewed clinical literature throughout. Key references: Hartgens & Kuipers (2004), Sports Medicine; Rahnema et al. (2014), Fertility & Sterility; Baggish et al. (2017), Circulation; Pope HG et al. (multiple), Harvard Medical School; Maravelias et al. (2005), Toxicology Letters; Achar et al. (2010), American Journal of Cardiology; Hart et al. (2001), NEJM.